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Introduction . The aim of the study was to analyse the survival and progression rates in patients with recurrent salivary 
gland cancer after surgery and adjuvant radio- or chemoradiotherapy. 
Material and methods . The study included 43 patients treated in 2006–2016 and evaluated in terms of PFS and OS.
Results . The 6-, 12- and 24-month OS rates were: 51%, 41%, and 14%, respectively, while the 6-, 12- and 24-month 
PFS rates were: 44%, 27%, and 14%, respectively. Any treatment improves OS and PFS, with surgery having the 
greatest effect on improving PFS, followed by chemotherapy and radiotherapy. A multivariate analysis has shown 
that predictors of PFS are: irradiated volume and radiation technique, while irradiated volume is the predictor of OS. 
Conclusions . Prognosis in patients with recurrent gland cancer is poor and does not depend on the type of relapse, 
but rather on further management.
NOWOTWORY J Oncol 2018; 68, 5–6: 245–252
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Introduction
Salivary gland neoplasms constitute from 3% to 11% 
of all cancers in the head and neck region and 0.2% of all 
cancers [1]. These neoplasms represent a diverse spectrum 
of tumours with the course of the disease based on such 
factors as: histopathology, tumour location and stage [2]. 
The relative rarity and significant diversity of these cancers 
prevent the widespread use of standardised therapy that is 
based on studies with the highest degrees of reliability. For 
this reason, treatment requires an individualised multidisci-
plinary approach and therapeutic decision-making based on 
a number of risk factors for relapse. These factors, according 
to different authors, include age, general condition, primary 
location, stage, surgical margin and histopathological type 
[3–4]. In the group of patients with locally advanced disease 
and with the risk factors described above, radical surgery 
followed by a radio- or chemoradiotherapy is the standard 
of care [5].
Despite such aggressive treatment, local recurrences are 
relatively frequent, and prognosis in patients with relapse is 
poor. The possibilities of surgical treatment are limited due 
to the location and infiltrative tumour growth. Moreover, 
the proximity of critical organs and the use of a tolerance 
dose in previously irradiated patients prevent conventional 
radiotherapy due to a high risk of complications. In nume-
rous cases, the only remaining treatment is conventional 
palliative chemotherapy or biological treatment, which is 
still being investigated. This study presents an analysis of 
a group of patients with recurrences after radical surgical 
treatment and adjuvant radio- or chemoradiotherapy in 
terms of overall survival and progression rate. An attempt 
was also made at the identification of risk factors that may 
affect the type of relapse, further treatment and prognosis.
Material and methods
The primary analysis involved 126 patients treated for 
cancer of the large salivary glands in the Centre of Oncology 
of the Lubelskie Region, Poland, in the years 2006–2016. These 
patients underwent radical surgery, followed by radical radio- 
or chemoradiotherapy. A retrospective analysis of the disease 
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history allowed the identification of 43 patients with a recur-
rent disease. Subsequently, a retrospective analysis involved 
both pre-defined clinical and epidemiological factors (type 
of involved salivary gland, sex, TNM stage, histopathological 
type, angio- or neuroinvasion at the diagnosis), as well as 
previous management (the extent of surgery, technique, 
dose and area of radiotherapy, and type of chemotherapy, 
if used). Moreover, epidemiological factors present at the 
time of relapse were also analysed, including the general 
condition (according to the WHO classification) and age at 
relapse as well as a patient’s further management (treatment 
or the lack of treatment and type of treatment). The patient 
characteristics are presented in Table I. The present study 
was approved by the Ethics Committee of the Lublin Medical 
University (Lublin, Poland) (approval no. 0254/340/2018). 
Written informed consent was obtained from all participants.
In the studied group, the following curves were analy-
sed: progression-free survival (PFS) and overall survival (OS). 
The Kaplan-Meier test was used for a statistical analysis. The 
study has investigated the impact of the above-described 
clinical and epidemiological factors as well as the type of 
management on OS and PFS. The log-rank test was em-
ployed to determine differences in OS and PFS between 
individual groups of patients. The Cox proportional hazard 
model was applied to analyse the influence of continuous 
independent variables on survival rates. When investiga-
ting the relationship between variables, the non-parametric 
Mann-Whitney U test (for independent variables) was used 
in order to compare the differences between two groups of 
patients, or the Kruskal-Wallis test was used to compare the 
differences between numerous groups of patients. To com-
pare the frequency of the analysed categories depending 
on the studied parameters, the nonparametric chi-square 
test (for qualitative variables) was applied. The significance 
level in all tests was p = 0.05. The statistical calculations were 
performed in Statistica ver. 13.1. (StatSoft Poland).
Results
Of all 43 relapses, 28 (65%) were locoregional. There 
were 22 relapses in the surgical bed (these were recurrences 
in the primary tumour area, in the area of removed salivary 
glands and in the area of primarily involved lymph nodes). 
In 6 patients, recurrences were observed in the regional 
lymph nodes beyond the surgical bed. Only one of these 
recurrences was found beyond the irradiated area. Of 11 
systemic relapses, 7 occurred in the lungs, 3 in the liver, 2 
in the bones, 2 in the brain and 1 in the mediastinal lymph 
nodes (Tab. I).
Table I . Characteristics of patients
Number of patients with relapses All Local relapses Generalised relapse
43 (100%) 28 (65%) 15 (35%)
Type of relapse*
Local
in bed
in regional lymph nodes
Generalised
in lung
in liver
in bones
in brain 
in non-regional lymph nodes
28 (65%)
22 (51%)
6 (14%)
15 (35%)
7 (16%)
3 (7%)
2 (5%)
2 (5%)
1 (2%)
28 (100%)
22 (79%)
6 (21%)
0
0
0
0
0
0
0
0
0
15 (100%)
7 (47%)
3 (20%)
2 (13%)
2 (13%)
1 (7%)
Age** 62,5 (20–88) 65,2 (44–88) 54 (20–75)
Sex*
female
male
24 (56%)
19 (44%)
15 (54%)
13 (46%)
9 (60%)
6 (40%)
General condition*
WHO 1
WHO 2
WHO 3
25 (58%)
15 (40%)
3 (7%)
15 (54%)
11 (39%)
2 (7%)
10 (67%)
4 (27%)
1 (7%)
Type of salivary gland*
parotid
submandibular
25 (58%)
18 (42%)
16 (57%)
12 (43%)
9 (60%)
6 (40%)
Primary radicality*
R0
R1
R2
23(54%)
17 (40%)
3 (7%)
15 (54%)
10 (36%)
3 (11%)
8 (53%)
7 (47%)
0
Histopathologic type*
squamous 
adenocarcinoma
12 (28%)
9 (21%)
10 (37%)
5 (19%)
2 (13%)
4 (27%)
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Number of patients with relapses All Local relapses Generalised relapse
43 (100%) 28 (65%) 15 (35%)
Histopathologic type*
undifferentiated
adenoid-cystic
acinic
others
7 (16%)
5 (12%)
4 (9%)
6 (14%)
1 (4%)
5 (19%)
3 (11%)
4 (15%)
6 (40%)
0
1 (7%)
2 (13%)
Neuroinvasion*
yes
no
19 (44%)
24 (56%)
11 (39%)
17 (61%)
8 (53%)
7 (47%)
Angioinvasion*
yes
no
7 (16%)
36 (84%)
5 (18%)
23 (82%)
2 (13%)
13 (87%)
Primary stage*
I
II
III
IV
1 (2%)
7 (16%)
10 (23%)
25 (58%)
0
5 (18%)
8 (29%)
15 (54%)
1 (7%)
2 (13%)
2 (13%)
10 (67%)
Tumour*
1
2
3
4
2 (5%)
10 (23%)
13 (30%)
18 (42%)
0 
6 (22%)
11 (41%)
10 (37%)
1 (7%)
4 (27%)
2 (13%)
8 (53%)
Nodes*
positive
negative
22 (51%)
21 (49%)
16 (57%)
12 (43%)
6 (40%)
9 (60%)
Time to wait for adjuvant treatment*
≤ 9 weeks
> 9 weeks
21 (49%)
22 (51%)
13 (46%)
15 (54%)
8 (53%)
7 (47%)
Type of surgery*
tumour excision
salivary excision
tumour/salivary excision with selective lymphadenctomy
tumour/salivary excision with unilateral lymphadenctomy
tumour/salivary excision with bilateral lymphadenctomy
9 (21%)
5 (12%)
11 (26%)
16 (37%)
2 (5%)
7 (25%)
3 (11%)
8 (29%)
9 (32%)
1 (4%)
2 (13%)
2 (13%)
3 (20%)
7 (47%)
1 (7%)
Radiation therapy planning technique*
2D
3D
IMRT
11 (26%)
11 (26%)
21 (48%)
9 (32%)
6 (21%)
13 (46%)
2 (13%)
5 (33%)
8 (53%)
Dose*
< 60 Gy
≥ 60 Gy
15 (35%)
28 (65%)
10 (36%)
18 (64%)
5 (33%)
10 (67%)
Radiation area*
only surgical bed with margin
surgical bed + LND group I–II
surgical bed + unilateral LND 
surgical bed + bilateral LND
7%
8%
12%
16%)
5 (18%)
5 (18%)
10 (36%)
8 (29%)
2 (13%)
3 (20%)
2 (13%)
8 (53%)
Chemotherapy + radiotherapy*
yes
no
8 (18%)
35 (82%)
6 (21%)
22 (78%)
2 (13%)
13 (87%)
Treatment after relapse*
Yes
surgery
radiotherapy
chemotherapy
No
37 (86%)
11 (26%)
7 (16%)
19 (44%)
6 (14%)
23 (82%)
11 (39%)
4 (15%)
8 (29%)
5 (18%)
14 (93%)
0
3 (20%)
11 (73%)
1 (7%)
Progression after relapse*
yes
no
37(86%)
6 (14%)
23 (82%)
5 (18%)
14 (93%)
1 (7%)
* number of patients (percent),** median (range), R0 — radical resection, T — tumour stage in TNM classification, N — nodal status in TNM classification, R1 — 
microscopically non-radical resection, R2 — macroscopically non-radical resection, 2D — two-dimensional planning, 3D — three-dimensional planning, IMRT — 
Intensity-modulated radiation therapy, Gy — gray
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The median follow-up of relapsed patients was 5.16 
months (0.1–65 months). Six of 86 patients (14%) died 
during this period. The probability of overall survival at 6 
months, 12 months and 24 months was 51%, 41%, and 14%, 
respectively. The median survival over the entire period was 
4.96 months (0.1–62.07 months) (Fig. 1). Of 43 relapses, 
further disease progression occurred in 37 (86%) patients 
(including 6 patients who did not receive any treatment 
due to relapse). The 6-, 12-, and 24-month probability of 
progression-free survival was 44%, 27% and 14%, respec-
tively (Fig. 2). 
The frequency of various types of relapse was also analy-
sed depending on risk factors. There were statistically signi-
ficant differences in the frequency of relapses depending on 
age. In younger patients, systemic relapses were more frequ-
ent, while local recurrences predominated in older patients. 
The results were statistically significant (Mann Whitney U 
Test Z = 2.459, p = 0.014). Moreover, there were statistically 
significant differences in the frequency of various relapses 
depending on the result of a histopathological examina-
tion (χ2 test = 12.935, p = 0.024). It was demonstrated that 
local recurrences predominate in squamous cell carcinoma, 
adenocarcinoma, adenoid cystic carcinoma, acinic cell carci-
noma and other types of carcinoma (83%, 56%, 100%, 75% 
and 66%, respectively), while systemic relapses were more 
common in undifferentiated cancer (100%). Differences in 
the occurrence of the remaining analysed factors were not 
statistically significant (p > 0.05).
The influence of epidemiological factors on overall and 
progression-free survival in patients with recurrences after 
surgery and adjuvant chemoradiotherapy was also analysed. 
There were no statistically significant differences in overall 
survival and progression-free survival depending on age, sex 
and type of involved salivary gland (submandibular or paro-
tid). However, a statistically significant difference in OS was 
found depending on the general condition. The likelihood 
of 6-, 12-, and 24-month survival in patients with WHO per-
formance status 0–1 was 64%, 51%, and 23%, respectively, 
in patients with WHO 2: 40%, 33%, and 6%, respectively, and 
in patients with WHO 3: 0%. A statistically significant diffe-
rence depending on the general condition was also found 
for PFS. The likelihood of 6-, 12-, and 24-month survival in 
patients with WHO performance status 0–1 was: 56%, 30%. 
and 20%, respectively, in patients with WHO 2: 34%, 27% 
and 7%, respectively, and in patients with WHO 3: 0%. There 
was also a statistically significant difference in the probabi-
lity of overall survival depending on the histopathological 
type of tumour. Six-month survival was observed in 33% 
of patients with squamous cell carcinoma, 50% of patients 
with undifferentiated cancer, 57% of patients with acinic 
cell carcinoma, 77% of patients with adenocarcinoma and 
100% of patients with adenoid cystic cancer. Differences 
in the probability of progression-free survival depending 
on the histopathological type were of borderline statistical 
significance. Local control at 6 months was observed in 33% 
of patients with squamous cell carcinoma, 43% of patients 
with undifferentiated cancer, 50% of patients with acinic 
cell carcinoma, 66% of patients with adenocarcinoma, and 
80% of patients with adenoid cystic cancer. The likelihood 
of 12- and 24-month OS and PFS was not assessed due 
to a low number of observations. A difference in PFS of 
borderline statistical significance was demonstrated for 
the primary lymph node status. Primarily N+ patients had 
shorter survival rates (6-, 12- and 24-month OS rates in the 
N+ group were 41%, 31%, and 7%, respectively, while in the 
N- group, the rates were: 59%, 50%, and 23%, respectively). 
Furthermore, the study revealed a statistically significant 
difference in PFS depending on the primary technique of 
radical RT. Patients receiving postoperative IMRT or 3D RT 
had longer PFS rates than those undergoing 2D RT (6, 12 
and 24-month PFS for IMRT was: 54%, 27%, and 18%, re-
spectively; for 3D RT; 57%, 30%, and 18%, respectively; for 
2D RT: 18%, 5%, and 0%, respectively). Similarly, longer 
PFS was observed in patients irradiated postoperatively 
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Figure 1 . Overall survival in all patients with relapses
Figure 2 . Progression free survival in all patients with relapses
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only to the area of the surgical bed or regional lymph no-
des (group I–II) (6-, 12- and 24-month PFS was: 53%, 47%, 
and 27%, respectively) compared to patients with radiation 
administered to all cervical lymph nodes, either uni- or 
bilaterally (6, 12 and 24-month PFS was 39%, 16%, and 5%, 
respectively). There were no statistically significant diffe-
rences regarding the dose of radical radiotherapy and the 
use of previous chemotherapy. Moreover, the influence of 
the type of chemotherapy for cancer recurrence on OS and 
PFS was also analysed. Platinum-based chemotherapy was 
used as second-line treatment in 13/18 patients (72%). The 
remaining patients received a monotherapy with paclitaxel. 
There were no statistically significant differences in OS (χ2 
= 0.412, p = 0.680) or PFS (χ2 = 0.049, p = 0.960) between 
these groups of patients (Tab. II).
Patients with locoregional and distant recurrences had 
similar prognoses. There were no statistically significant 
differences in OS or PFS. However, there were statistically 
significant differences in patient management. Patients who 
received any treatment had better prognosis than those 
without treatment. Patients undergoing surgery due to 
recurrence had the best prognosis (6-, 12- and 24-month OS 
was: 81%, 61%, and 40%, respectively; 6-, 12- and 24-month 
PFS was: 82%, 51%, and 31%, respectively), followed by 
patients receiving chemotherapy (6-, 12- and 24-month 
OS: 58%, 53%, and 12%, respectively, 6-, 12- and 24-month 
PFS: 47%, 25%, and 14%, respectively). The shortest PFS 
was noted in patients undergoing palliative radiotherapy 
(6-, 12- and 24- month OS: 28%, 15%, and 15%, respecti-
vely, and 6-, 12- and 24-month PFS: 14%, 14%, and 14%, 
respectively). Patients receiving no treatment had very poor 
prognosis (6-month OS = 0%, 6-month PFS = 0%) (Tab. II). 
Moreover, Cox’s multivariate analysis showed that the only 
independent predictor of overall survival was the irradiated 
area (χ2 = 4.395, HR 1.439 (1.023–2.013) p = 0.036) in posto-
perative treatment. Patients with a smaller area irradiated 
had a more favourable prognosis.
Also, independent predictors of progression-free survi-
val in patients with relapse after radical treatment included: 
irradiated area (χ2 = 9.727, HR 1.863 (1.260–2.755) p = 0.002) 
and radiation technique (χ2 = 5.281, HR 0.542 (0.321–0.913) 
p = 0.022). Patients in whom a smaller area was irradiated 
with a more modern planning technique were characterised 
by better prognosis.
Of all relapses, locoregional relapses accounted for 63% 
(28/43). Of these, 22 relapses (51%) occurred within the 
surgical bed, while the remaining 6 (14%) developed in the 
cervical lymph nodes. As for the factors that may have had 
an influence on the type of relapse, statistically significant 
differences were noted for the type of surgical treatment. 
It was demonstrated that locoregional recurrences beyond 
the surgical bed were significantly more frequent after se-
lective lymphadenectomy (50%, 4/8 relapses) than after 
other types of surgical treatment (χ2 = 10.842, p = 0.028). The 
use of simultaneous chemoradiotherapy was characterised 
by borderline significance (χ2 = 3.702, p = 0.054). Patients 
who received chemotherapy tended to develop recurrences 
beyond the surgical bed (3/6, 50%), while all those who did 
Table II . The impact of various factors on the PFS OS
Factor OS PFS
Chi-square p Chi-square p
Age 0.540 0.910 0.833 0.842
Sex 0.307 0.759 0.206 0.837
WHO 10.036 0.006 8.698 0.013
Type of salivary gland 0.058 0.954 0.640 0.949
Histopathologic type 12.034 0.034 10.594 0.050
Neuroinvasion 0.448 0.654 0.509 0.611
Angioinvasion 0.931 0.352 0.976 0.329
Tumour 4.070 0.264 4.924 0.177
Nodes 1.883 0.049 1.810 0.070
Type of surgery 1.674 0.093 1.103 0.270
Dose 1.136 0.255 0.764 0.445
Radiation therapy planning technique 1.794 0.073 6.069 0.048
Radiation therapy area 2.005 0.045 2.055 0.039
Chemotherapy 0.839 0.402 0.176 0.860
Type of relapse 0.438 0.661 0.721 0.471
Treatment yes/no 2.385 0.017 2.500 0.012
Type of treatment 4.815 0.090 7.409 0.024
OS — overall survival, PFS — progression free survival, p — level of significance
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not receive chemotherapy mostly had relapses within the 
surgical bed (19/23, 83%). As for other factors, differences 
were not statistically significant (p > 0.05). In patients with 
local recurrence, 23 patients (81%) were treated: all patients 
with relapses beyond the surgical bed and 17 patients (77%) 
with a relapse within the surgical bed. Differences were 
not statistically significant in these patients (χ2 = 1.660, 
p = 0.197). In the treated patients, all with a relapse within 
the surgical bed were re-operated (11/11, 100%), 2/2 (50%) 
underwent re-radiation, and 4/8 (50%) underwent che-
motherapy. These differences were statistically significant 
(χ2 = 4.212, p = 0.024).
The analysis of survival in the group of patients with local 
recurrences showed that 6-, 12- and 24-month OS was 53%, 
38%, and 17%, respectively, while the 6-, 12- and 24-month 
PFS was 50%, 27%, and 13%, respectively. There were no 
statistically significant differences in OS between patients 
with a relapse within the surgical bed and in the regional 
lymph nodes (χ2 = 0.442, p = 0.658). The probability of 6-, 
12- and 24-month OS in patients with surgical bed relapses 
was 46%, 36%, and 18%, respectively, and in patients with 
nodal recurrences: 83%, 42%, and 0%, respectively. Similar-
ly, there were no statistically significant differences in PFS 
between patients with a relapse in the surgical bed and 
regional lymph nodes (χ2 = 0.689, p = 0.490). The probability 
of 6-, 12- and 24-month PFS in patients with surgical bed 
relapses was 46%, 23%, and 14%, respectively, and with 
nodal recurrences: 67%, 45%, and 0%, respectively.
Of 15 systemic relapses, 7 (47%) developed in the lungs, 
3 (20%) in the liver, 2 (13%) in the bones, 2 (13%) in the brain, 
and 1 (7%) in the extra-regional lymph nodes (mediastinal 
nodes). No statistically significant factors were found that 
could affect the frequency of a given type of relapse. The 
survival analysis in the group of patients with local recur-
rences showed that 6-, 12- and 24-month OS was 46%, 40%, 
and 13%, respectively, while 6-, 12- and 24-month PFS was 
33%, 27%, and 14%, respectively. There were no statistically 
significant differences in OS (χ2 = 0.432, p = 0.979) or PFS 
between patients with relapse in different sites (χ2 = 3.216, 
p = 0.522).
Of 43 relapses, further progression was found in 37 
patients. In patients with local recurrences, 7 (16%) had 
local progression, 5 (12%) distant metastases, and 5 (12%) 
had both local progression and distant metastases. As for 
the remaining patients, there were no data on the type of 
progression. Among patients with systemic relapse, 5 pa-
tients suffered further progression of the size and number 
of metastases. In the remaining patients, data on the type 
of progression remain unknown. Of 37 patients with pro-
gression, next-line treatment was administered to 4 patients 
— only those with local recurrences. The median PFS in 
these patients was 5 months (2–26 months). Three patients 
suffered from disease dissemination (to the lungs and to 
the liver in one case), and one patient presented with local 
progression. All patients received palliative chemotherapy, 
and one was treated with palliative brachytherapy to 20 Gy 
in 5 fractions of 4 Gy. Various treatment regimens were used 
(paclitaxel with carboplatin and cisplatin, navelbine with 
fluorouracil, doxorubicin with cyclophosphamide). Another 
chemotherapy line was given to two patients. Ifosfamide 
monotherapy (IFO 7) and palliative brachytherapy (10 Gy in 
1 fraction) were used. In the patient treated with ifosfamide, 
PFS was 3 months, and in the patient treated with brachy-
therapy, it was 1 month.
Discussion
The above analysis shows that prognosis in patients with 
recurrent salivary gland cancer after surgery and adjuvant 
radio- or chemoradiotherapy is poor. Six-, 12-, and 24-month 
OS was only 51%, 41%, and 14%, respectively, and 6-, 12- and 
24-month PFS was 44%, 27%, and 14%, respectively. The 
prognosis was not different between patients with local 
and systemic relapse. However, it was dependent on the 
type of employed treatment. Patients eligible for salvage 
surgery presented the best prognosis, but prognosis was 
worse in those treated with chemotherapy or radiotherapy 
(12-month PFS was 51%, 25% and 14%, respectively).
Studies on treatment of recurrent salivary gland cancer 
are limited to very small groups of patients and based on 
single-centre retrospective analyses. In the vast majority of 
these studies, survival outcomes are better, but the patient 
profile in all of these studies varies from the one in the pre-
sent study. This analysis is predominated by squamous cell 
carcinoma, which has poor prognosis, and most patients 
were initially at an advanced stage (75% of patients in stages 
III and IV). For example, Spiro et al. [6] report 5-year OS at 
a level of 30% in patients treated surgically due to relapse, 
and Kobayashi et al. [7] observed 5-year OS of 67% in a 
group of only 12 patients after salvage surgery. However, it 
should be noted that these patients presented a favourable 
prognosis, because the remaining 8 patients from this gro-
up, with a disease assessed as inoperable, survived over 3 
years on average. The outcomes after repeated radiotherapy 
also indicate positive treatment results. Pederson et al. [8] 
employed repeated radiation therapy to a dose of 32–66 
Gy, which resulted in 1-month and 3-month OS at a level 
of 72% and 52%, respectively. In the patients described in 
the present study, the outcomes were also worse. However, 
only 4 patients underwent repeated radiation therapy, and 
all others received palliative radiotherapy. Moreover, data 
on the use of chemotherapy are also based on small groups 
and diverse treatment regimes, which makes it very difficult 
to draw unambiguous conclusions. Treatment responses 
vary from 0% to 100% with response period of 6–9 months 
[9]. As in the analysed group of patients, platinum-based 
regimens prevailed [10].
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The present study analysed the influence of various fac-
tors on prognosis in patients with recurrent cancer. A multi-
variate analysis showed that patients irradiated to a smaller 
area presented better prognosis. This could be related to 
both lower initial cancer stage and better possibilities of 
salvage treatment (easier surgical treatment, greater po-
ssibilities of using repeated radiation therapy and lower 
risk of complications related to less aggressive treatment). 
Moreover, prior irradiation using modern planning techni-
ques improved prognosis. The reasons for this may have 
been similar to those described above. Studies on primary 
tumour treatment indicate worse prognosis in patients with 
squamous cell carcinoma and undifferentiated cancer [11]. 
These histopathological types were also characterised by 
the worst prognosis in patients with the recurrent disease. 
Patients who were less advanced at the diagnosis and in bet-
ter general condition presented a better prognosis, which 
seems to be obvious.
Based on the investigated patients, it was shown that 
systemic relapses are more common in younger patients, 
while local recurrences occur more often in older patients. 
These results are difficult to interpret in the light of rese-
arch which indicates that younger patients tend to develop 
slow-growing local diseases (adenoid cystic and mucoepi-
dermoid carcinoma), while more aggressive types occur in 
older individuals (NOS adenocarcinoma) [12, 13]. However, it 
should be noted that the patient profile was slightly different 
in the examined group of patients (all patients were initial-
ly at a higher risk of relapse and were therefore deemed 
eligible for adjuvant treatment). The analysis of the site of 
relapse depending on the histopathological type showed 
that patients with undifferentiated cancer were characte-
rised by disease progression mainly in the form of distant 
metastases, whereas the remaining histopathological types 
were characterised by the predominance of local recurren-
ces. This is probably related to the aggressiveness of this 
tumour compared with other histopathological types [14].
The role of chemotherapy combined with radiothe-
rapy in the treatment of salivary gland tumours remains 
unclear. The study of relapsed patients does not indicate 
that the number of systemic relapses is lower in patients 
treated with a combination therapy compared to patients 
who received only postoperative radiotherapy. It was only 
shown that patients treated with radiotherapy combined 
with chemotherapy less often developed recurrences in 
the irradiated area, and the difference was on the verge of 
statistical significance. This may lead to a conclusion that 
chemotherapy probably increases local effectiveness of 
radiotherapy, which is supported by some studies [15–18]. 
Moreover, the study also indicates that a decision regarding 
the extent of surgery is crucial. In the analysed group of 
patients, nodal progression beyond the surgical bed was 
significantly more frequent in patients treated with selective 
lymphadenectomy than in those receiving radical lympha-
denectomy, which indicates the need for high caution when 
selecting patients for this method of surgical treatment.
Conclusions
The prognosis in patients with recurrent salivary gland 
cancer after surgery and adjuvant radio- or chemoradio-
therapy does not depend on the type of relapse, but rather 
on further management. Patients in whom any treatment 
is implemented present better prognosis. In this group, 
prognosis was the best in patients undergoing surgery, 
followed by those treated with chemotherapy, and the worst 
in those receiving radiation therapy. Moreover, general con-
dition, cancer stage, histopathological type, radiotherapy 
technique, and irradiated volume, which can be directly 
related to the stage of the disease, also contribute to the 
success of treatment. Distant metastases are more common 
in younger patients with undifferentiated cancer. The prior 
use of chemotherapy and the extent of lymphadenectomy 
may also be of prognostic significance.
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